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PCRAbstract Dissemination of carbapenem resistance via Enterobacteriaceae, particularly among
Klebsiella pneumoniae and Escherichia coli, is a major public health concern. Rapid methods for
determining antimicrobial susceptibility are important to ensure adequate and appropriate use of
antimicrobial agents and to limit the spread of these bacteria. In the current study, we compared
the rapidity, sensitivity and specificity of traditional methods and molecular-based Xpert Carba-
R PCR assay to identify sixty isolates, (26 E. coli and 34 K. pneumoniae). The specificity of MicroS-
can was 100% while sensitivity to ertapenem (ERT), imipenem (IMI), and meropenem (MER) was
93%, 68.9%, and 55.17%, respectively. For the modified Hodge test, the specificity was 96.77% and
sensitivity was 89.65%. Although some results of phenotypic assays matched with the definite PCR
identification, some results were misleading. Out of the 29 positive PCR samples, three samples of
K. pneumoniae were negative for the MHT and one E. coli sample was MHT positive but negative
for the PCR. Nine samples were positive for the PCR but were determined as carbapenem sensitive
by MicroScan. While MicroScan and MHT requires several hours and multi-steps to obtain results,
Xpert Carba-R PCR assay takes less than an hour. Therefore, we recommend using Gene xpert
Carba-R assay for the optimal carbapenemnase detection with reducing material, manpower and
cost. Also it is important to know the type of carbapenemase is present.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Enterobacteriaceae comprises a group of gram negative bacte-
ria that are known to cause several important infections such
as urinary tract infections, cystitis, wound sepsis, pneumonia,
bacteremia, and meningitis (Mitchell and Yehuda, 2008). Mul-
tiple antibiotic resistance, particularly resistance to car-
bapenem, among Enterobacteriaceae is a major public health
156 M. AlTamimi et al.concern. Carbapenem-resistant Enterobacteriaceae, reported
mostly in hospital-associated infections, is associated with
more than 50% mortalities which poses a great challenge in
patient care units (Poirel et al., 2011; Brink et al., 2011;
Munoz-Price et al., 2014; McLaughlin et al., 2014;
Nordmann, 2014). Resistance to carbapenems is attributed
to the ability to produce three different categories of carbapen-
emases; (1) class A (serine carbapenemases, such as Klebsiella
pneumoniae carbapenemase (KPC)), (2) class B, metallo-b-
lactamases, such as IMP, VIM, and NDM, and (3) class D
(OXA carbapenemases, such as OXA-23 and OXA-48)
(Queenan and Bush, 2007; Miriagou et al., 2010).
The rapid identification of carbapenem resistance organisms
is critical not only for the initiation of the proper antimicrobial
regimen but also for stopping their spread. Several phenotypic
methods are available for detection of carbapenemase enzymes
such as; modified Hodge test (MHT), combined disk test
(CDT) and inhibitor based E-test. However, none of the cur-
rent phenotypic tests offer optimal sensitivities and specificities.
Modified Hodge test (MHT) has been extensively used as a
specific method to detect un-typed carbapenemase activity
and is currently the only method recommended by the Clinical
and Laboratory Standards Institute (CLSI) (Orstavik and
Odegaard, 1971). Although MHT is useful for detection of car-
bapenemases, it has low sensitivity (Girlich et al., 2012) and low
specificity for metallo-enzymes (Cuzon et al., 2011; Girlich
et al., 2012). In addition, MHT may produce false positive
results mainly due to CTX-M-producing strains with reduced
outer membrane permeability and high-level AmpC-
producers (Girlich et al., 2008; Pasteran et al., 2009). Similarly
for the inhibitor-based E-test, a test for detection of K. pneumo-
niae carbapenemases (KPC), false-positive test results may
occur if AmpC b lactamases are coproduced (Pasteran et al.,
2009; Pournaras et al., 2010; van Dijk et al., 2014).
Thus, phenotypic methods are growth dependent and time-
consuming as it takes 18–24 h to completion, not clinically use-
ful and results are also subjective (Cuzon et al., 2011; Girlich
et al., 2012). Therefore, identification by molecular methods
such as real time-PCR have been shown to be sensitive and
more accurate for identification of carbapenemase genes.
Moreover, diagnosis by molecular methods is comparatively
faster than phenotypic assays as the extra overnight incubation
step is superfluous. (Manchanda et al., 2011; Liu et al., 2012;
Rachana et al., 2014). The current study was designed to eval-
uate and compare the sensitivity and specificity of the pheno-
typic assays, MHT, MicroScan, and E-test, with Gene
Expert Carba-R assay, as a rapid, low-cost real-time PCR
method, for the detection of carbapenemase-producing K.
pneumoniae and E. coli isolates in Riyadh region.
2. Materials and methods
2.1. Bacterial isolates and culture conditions
Sixty non-duplicated isolates were collected from patients
admitted to Prince Sultan Military Medical City in Riyadh,
Saudi Arabia from 2014 to 2015. Both outpatients and inpa-
tients were included and samples were obtained from urine.
Isolates were maintained by routinely culturing on blood agar
(BA) plates and MacConkey agar plates for 18–24 h at 37 C.
Identification of the isolates were performed using severalassays such as colonial morphology, Oxidase test, API 20E
(bioMerieux, Inc) and MicroScan walkaway 96 plus (SIE-
MENS Healthcare diagnostics). Of the sixty isolates, twenty
six were E. coli and thirty four were K. pneumoniae.
2.2. Phenotypic screening of carbapenemases
2.2.1. Antimicrobial susceptibility tests by MicroScan system
Resistance to and MIC values of 14 antibiotics including imi-
penem, meropenem, ertapenem were determined by MicroS-
can walkaway 96 plus (SIEMENS Healthcare diagnostics) as
described by manufacturer’s instructions. Briefly, 0.5 McFar-
land bacterial suspension from each isolate was prepared and
transferred to the gram negative bacteria panel (Neg panel
Type 49). Following 18–24 h incubation, MIC values were
obtained and analyzed according to the standard Clinical
and Laboratory Standards Institute, 2014 guidelines (CLSI).
Isolates that were resistant to imipenem, meropenem or ertape-
nem were considered carbapenem-resistant.
2.2.2. Modified Hodge test (MHT)
The ability of carbapenem-resistant isolates to produce car-
bapenemases was investigated by MHT technique. Briefly,
0.5 McFarland suspension of carbapenem susceptible strain
E. coli ATCC 25922 was streaked as a lawn over Mueller Hin-
ton agar (MHA) plates and disks loaded with meropenem
(10 lg) or ertapenem were placed in the center of the test area.
Isolates to be tested along with a positive control (K. pneumo-
niae ATCC1705) and negative control (K. pneumoniae
ATCC1706) were streaked as straight lines from the edge of
the meropenem disk to the edge of the plate. Inoculated plates
were allowed to dry for 15 min at room temperature and incu-
bated overnight at 35 ± 2 C for 16–24 h. The test was consid-
ered positive when a clover leaf-like shape was observed.
2.3. Molecular Xpert Carba-R assay
Xpert Carba-R (Cepheid, Sunnyvale, USA) is a fully auto-
mated and integrated system for sample preparation, DNA
extraction, amplification and qualitative detection of target
genes using multiplex real time PCR assays. This new assay
involves a single-use disposable cartridge that holds PCR
reagents and hosts the PCR processes. The cartridge contains
primers that target and amplify a number of carbapenemase
resistance genes; blaIMP, blaVIM, blaNDM, blaKPC, and
blaOXA-48. Xpert Carba-R assay kit contains sufficient reagents
to process 10 samples. In addition, it contains a positive con-
trol which carries all the 5 beta-lactamase gene sequences
detected and negative control with no beta-lactamase gene
sequences. Isolates to be tested were inoculated into the sample
reagent and loaded into the cartridge as described by manufac-
turers’ instructions. Results were analyzed using GeneXpert
Software Version 4.3.
3. Results
3.1. Antibiotic susceptibility of E. coli and K. pneumoniae
MicroScan antibiotic susceptibility profile of the 60 clinical
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Figure 1 Antibiotic resistance profile of the 60 isolates of E. coli
and K. pneumoniae as determined by MicroScan. (R = resistant,
I = intermediate, S = sensitive).
Table 2 Modified Hodge test results of isolates (n= 60).
Number of isolates (%)







23 (38.3%) 11 (18.3%)
E. coli (n= 26) 4 (6.6%) 22 (36.6%)
Total (n= 60) 27 (45%) 33 (55%)
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only 3 (5%) isolates of E. coli were resistant to imipenem, mer-
openem and ertapenem (Table 1). Of the 26 E. coli isolates, 3
(11.5%), 2 (7.69%), and 3 (12%) were resistant to imipenem,
meropenem and ertapenem, respectively, while 22 (84.6%),
24 (92.3%) and 23 (88%) were sensitive to imipenem, merope-
nem and ertapenem, respectively. Only one (4%) isolate exhib-
ited intermediate susceptibility to imipenem. For the 34 K.
pneumoniae isolates, 11 (32%), 12 (35%), and 24 (70.58%)
were resistant to imipenem, meropenem and ertapenem,
respectively, while 17 (50%), 20 (59%) and 10 (29.4%) were
sensitive to imipenem, meropenem and ertapenem, respectively
(Fig. 1). Only 2 (6%) and 6 (18%) isolates exhibited interme-
diate susceptibility to meropenem and imipenem, respectively.
Interestingly, these isolates have high resistance values against
other antibiotics as indicated from MICs. Five (19%) out of 26
E. coli isolates and 19 (52.7) out of 36 K. pneumoniae were
defined as multi drug resistant isolates. Of the 60 isolates only
2 (3.3%) were resistant to all the tested antibiotics except Ami-
kacin and only two were sensitive to all antibiotics. Five
(14.7%) of K. pneumoniae isolates were resistant to all tested
antibiotics but exhibited intermediate susceptibility to Amika-
cin. Only one E. coli isolate was sensitive to all antibiotics
except for Ampicillin.
3.2. Carbapenem resistant isolates produce carbapenemase
The ability of E. coli and K. pneumoniae isolates to produce
carbapenemases was tested using MHT. Out of the 60 isolates,
26 (43%) were positive for carbapenemase production. Of
these, 23 (67.6%) out of 34 isolates were positive for K. pneu-
moniae and only 4 out of 26 were positive for E. coli (Table 2
and Fig. 2).
3.3. Rapid identification of carbapenem genes using Gene Xpert
Carba-R assay
A total of 60 isolates were tested by the Xpert Carba-R Assay
for the target carbapenem-resistant gene sequences (blaIMP,
blaVIM, blaNDM, blaKPC, and blaOXA-48). The results wereTable 1 Overall rates of antibiotics susceptibility test of E. coli (
MicroScan.
Antibiotics R* n (%) I* n (%)
E. coli K. pneum. E. coli K. pne
Ertapenem 3 (11.5) 24 (70.5) 0 0
Imipenem 3 (11.5) 11 (32.3) 1 (3.8) 6 (17.6
Meropenem 2 (7.6) 12 (35.2) 0 2 (5.8)
Amikacin 2 (7.6) 12 (35.2) 0 10 (29.
Amox/kclav 9 (3.6) 29 (85.8) 5 (19) 2 (5.8)
Ampicillin 25 (96) 33 (97) 0 0
Cefepime 25 (96) 27 (79) 0 1 (2.9)
Cefotaxime 4 (15.3) 17 (50) 0 0
Ceftazidime 4 (15.3) 16 (47) 0 0
Cefuroxime 25 (96) 32 (94) 0 0
Ciprofloxacin 15 (57.6) 29 (85) 0 0
Gentamicin 15 (57.6) 23 (67.6) 1 (3.8) 0
PipTzo 6 (23) 27 (79) 1 (3.8) 1 (2.9)
TrimethSulfa 16 (61.5) 18 (53.9) 0 0
* (S = sensitive, R = resistant, I = intermediate, ESBL = Extended spinterpreted by the Gene-Xpert software from measured fluo-
rescent signals and embedded calculation algorithms (Fig. 3).
PCR results indicated that 29 (48.3%) out of 60 isolates were
positive for carbapenem resistance determine genes. As shown
in Table 5, OXA-48 gene was the most frequent where it was
detected in 23 (38.33%) isolates, (1 (4%) isolate of E. coli,
and 22 (64.7%) isolates of K. pneumoniae), followed by
NDM in 4 (6.6%) isolates (2 (8%) in E. coli and 2 (5.8%) in
K. pneumoniae isolates), VIM was detected only in one isolaten= 26) and K. pneumoniae isolates (n= 34) as determined by
S* n (%) ESBL* n (%)
um. E. coli K. pneum. E. coli K. pneum.
23 (88.4) 10 (29.4) 0 0
) 22 (84.6) 17 (50) 0 0
24 (92.3) 20 (58.8) 0 0
4) 24 (92.3) 12 (35.2) 0 0
12 (46.1) 3 (8.8) 0 0
1 (3.8) 1 (2.9) 0 0
1 (3.8) 6 (17.6) 0 0
1 (3.8) 6 (17.6) 21 (80.7) 11 (32.3)
1 (3.8) 6 (17.6) 21 (80.7) 12 (35.2)
1 (3.8) 2 (5.8) 0 0
11 (42.3) 5 (14.7) 0 0
10 (38.4) 11 (32.3) 0 0
19 (73) 6 (17.6) 0 0
10 (41.2) 16 (47) 0 0
ectrum beta-lactamase).
Figure 2 Example of E. coli isolates showing a positive and negative results with MHT on Muller Hinton Agar. Symbols; (1) K.
pneumoniae negative control ATCC 1706. (2) E. coli 25922. (3) Meropenem disk. (4) K. pneumoniae positive control ATCC1705. (5)
Negative MHT result. (6) Positive MHT result.
A B
C D 
Figure 3 Gene Xperts Carba-R assay analysis. (A) OXA-48 gene detected in K. pneumoniae isolates, (B) NDM gene detected in E. coli
isolates, (C) VIM gene detected in K. pneumoniae isolates, and (D) positive control KPC of K. pneumoniae.
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detected in any of the tested isolates.
3.4. Rapidity, sensitivity and specificity of Xpert Carba-R assay
in comparison with phenotypic tests
The results showed a notable variation between phenotypic
assays, MicroScan and MHT, and molecular-based Xpert
Carba-R PCR assay in terms of rapidity, sensitivity and
specificity. The specificity of MicroScan was 100% while its
sensitivity to ETP, IMP, and MER was 93%, 68.9%, and
55.17%, respectively. For the modified Hodge test, the speci-
ficity was 96.77% and sensitivity was 89.65%. Although some
results of phenotypic assays matched with the definite PCR
identification, some results were misleading. Out of the 29 pos-
itive PCR samples (i.e. carbapenem resistant), three samples of
K. pneumoniae (samples; 1, 7, and 8) were negative for the
MHT and one E. coli sample was MHT positive but negative
for the PCR. For the MicroScan results, 9 samples (8 for K.
pneumoniae and 1 for E. coli) were determined as carbapenem
sensitive for (Imipenem and Meropenem). These 9 samples
were determined as carbapenem resistance by PCR (Table 5).
Another important item that should be considered is the time
factor. In the phenotypic assays where MicroScan takes
18–24 h and MHT 16-24 h, PCR takes less than an hour. From
the above findings, PCR is rapid, accurate and sensitive assay
for detection of carbapenem-resistant Enterobacteriaceae.4. Discussion
Enterobacteriaceae members such as E. coli and K. pneumoniae
are among the most important causative agents of hospital-
acquired and community-onset infections of human beings
(Paterson, 2006). Carbapenemases production by these bacte-
ria is associated with therapy failures, dissemination, and
increased mortality rates (Nordmann et al., 2011). Therefore,
reliable detection methods with rapidity, high sensitivity and
specificity is required (Nordmann, 2014). The rapid identifica-
tion of carbapenem resistance bacteria allows physicians not
only to describe the proper antimicrobial regimen but also to
restrict their spreading. The preliminary screening for car-
bapenemase producers in clinical specimens is based first on
phenotypic tests, whereas, confirmation tests are mainly based
on molecular assays. However, traditional phenotypic meth-
ods have some disadvantages such as; are time-consuming, dif-
ficult to interpret, and the sensitivity/specificity vary between
different species (Nordmann et al., 2011; Miriagou et al.,
2010; Cheng-Yen and Jiunn-Jong, 2015; Walsh et al., 2011).
The phenotypic assays, MHT has been suggested as the
gold standard technique to detect carbapenemase producing
bacteria in the past years (Nordmann et al., 2012). Of the 60
isolates tested in the current study, 27 (45%) were MHT pos-
itive (Table 2, Fig. 2). Our results showed that MHT failed to
detect one isolate of K. pneumoniae which was PCR positive
for NDM gene. As well, two K. pneumoniae isolates were
OXA-48 producers but were negative for MHT (Table 5).
The overall sensitivity and specificity of the MHT were
89.6% and 96.77%, respectively. Doyle et al., found that the
sensitivity and specificity for MHT was 61% and 93%, respec-
tively (Doyle et al., 2012). MHT is less reliable to detect
NDMs, VIMs, and IMPs producing bacteria; however, itmay be useful for detecting KPC and OXA-48 producers
(Nordmann et al., 2011; Castanheira et al., 2011; Doyle
et al., 2012).
Resistance to carbapenem agents is due to carbapenemase
and presence of other resistance mechanisms, such as ESBLs,
porin mutations and/or presence of efflux pumps (Chambers,
2010). In our study, carbapenem resistance rates among K.
pneumoniae isolates were 24 (70.5%), and 5 (19.2%) among
E. coli isolates, while we found 36 isolates sensitive suggesting
resistance mechanism other than carbapenemase production
(Rachana et al., 2014).
Most carbapenem resistant isolates had high resistance
rates against other antibiotics including amikacin, augmentin,
ampicillin, cefepime, cefotaxime, ceftazidime, ciprofloxacin,
cefuroxime, gentamicin, piperacillin/tazobactam, and
trimethoprim/ sulfamethoxazole (Table 1). The resistance rates
for carbapenem resistant K. pneumoniae isolates were 45.8%,
100%, 100%, 83.3%, 87.7%, 87.7%, 95.8%, 75%, 95.8%
and 62.5% respectively, while resistance rates for 5 isolates
of carbapenem resistant E. coli were 0%, 60%, 100%, 100%,
100%, 100%, 100%, 100%, 40%, 40%, 40% respectively.
Current study found that two isolates of K. pneumoniae
harbored OXA-48 gene exhibited sensitivity to IMI, MER
and ERT antibiotics by Microscan (Table 1, Fig. 1). As well,
seven isolates of K. pneumoniae produced OXA-48 gene and
seemed resistant only to ertapenem. For E. coli isolates, one
OXA-48 producer isolate exhibited resistance to ertapenem
but not for IMI or MER (Tables 1 and 5). Several studies
had reported that automated susceptibility systems incorrectly
labeled up to 87% of carbapenemase-producing K. pneumoniae
isolates as susceptible to imipenem (Tenover et al., 2006). Erta-
penem resistance seems to be a marker for carbapenemase pro-
duction when automated testing methods are used (Tenover
et al., 2006; Anderson et al., 2007). This necessitates further
testing by phenotypic and genotypic methods. If resources
are limited, an elevated MIC for ertapenem could be used as
a screening method to determine which isolates need further
testing (Tenover et al., 2006; Anderson et al., 2007).
Xpert Carba-R PCR assay can differentiate the most preva-
lent carbapenemase genes including KPC, NDM, VIM, OXA-
48 and IMP-1 in less than an hour. Tenover et al., 2013;
showed that the sensitivity and specificity of Xpert MDRO
for detecting KPC or VIM were 100% and 99.0%, respectively
(Tenover et al., 2013). Other study evaluated the performance
of three commercial molecular assays for detecting major fam-
ilies of carbapenemases; they found that the sensitivity and
specificity of Xpert Carba-R kit is 71–100% and 100% for dif-
ferent carbapenemase families (Findlay et al., 2015).
However, our study revealed high prevalence of OXA-48
type carbapenemase-producing in 24 (38.33%) isolates, fol-
lowed by NDM type in 5 isolates, VIM was found less detected
only in one isolate of K. pneumoniae (Table 3 and Fig. 3). The
absence of VIM-1, KPC and IMP genes suggest that these iso-
lates are not major sources of carbapenemases in the Kingdom
(Table 4). Zowawi et al., 2014; found that the most common
carbapenemases were of the OXA-48 and NDM respectively.
Other studies showed that the OXA-type carbapenemases is
a growing problem and the most important reason for resis-
tance to IMI and MER Acinetobacter’s worldwide (Gur
et al., 2008; Carvalho et al., 2009; Kuo et al., 2010). Other
studies performed in Saudi Arabia indicated that OXA-48
and NDM-1 types are the dominant carbapenemases among
Table 3 Gene Xperts Carba-R results in all isolates (n= 60).
No. KPC NDM VIM OXA-48 IMP-1 No. KPC NDM VIM OXA-48 IMP-1 NO. KPC NDM VIM OXA-48 IMP-1
1 ve +ve ve ve ve 21 ve ve ve ve ve 41 ve ve ve ve ve
2 ve ve ve +ve ve 22 ve ve ve ve ve 42 ve ve ve ve ve
3 ve ve ve +ve ve 23 ve ve ve ve ve 43 ve ve ve +ve ve
4 ve ve ve +ve ve 24 ve ve ve ve ve 44 ve ve ve ve ve
5 ve +ve ve ve ve 25 ve ve ve ve ve 45 ve ve ve ve ve
6 ve ve ve ve ve 26 ve ve ve ve ve 46 ve ve ve ve ve
7 ve ve ve +ve ve 27 ve ve ve ve ve 47 ve ve ve ve ve
8 ve ve ve +ve ve 28 ve ve ve ve ve 48 ve ve ve +ve ve
9 ve ve ve +ve ve 29 ve ve ve ve ve 49 ve ve ve +ve ve
10 ve +ve ve ve ve 30 ve ve ve ve ve 50 ve ve ve +ve ve
11 ve ve ve +ve ve 31 ve ve ve ve ve 51 ve ve ve +ve ve
12 ve ve ve +ve ve 32 ve ve ve ve ve 52 ve ve ve +ve ve
13 ve ve +ve ve ve 33 ve ve ve ve ve 53 ve ve ve +ve ve
14 ve ve ve +ve ve 34 ve ve ve ve ve 54 ve ve ve ve ve
15 ve ve ve +ve ve 35 ve +ve ve ve ve 55 ve ve ve ve ve
16 ve ve ve +ve ve 36 ve +ve ve ve ve 56 ve ve ve +ve ve
17 ve ve ve +ve ve 37 ve ve ve +ve ve 57 ve ve ve +ve ve
18 ve ve ve +ve ve 38 ve ve ve ve ve 58 ve ve ve +ve ve
19 ve ve ve ve ve 39 ve ve ve ve ve 59 ve ve ve ve ve
20 ve ve ve ve ve 40 ve ve ve ve ve 60 ve ve ve ve ve
Samples number; 1–16, 18, 21, 26, 31, 36–38, 40, 45–51, 54–56 are for K. pneumoniae and samples number; 17, 19, 20, 22, 23–25, 27–30, 32–35,
39, 41–44, 52, 53, 57–60 are for E. coli.
Table 4 Prevalence of carbapenem resistance determining
genes among all isolates (n= 60).
Carbapenem resistance
genes







160 M. AlTamimi et al.the Enterobacteriaceae (Memish et al., 2014). The emergence
of OXA-48 and NDM carbapenemases among the Enterobac-
teriaceae in Saudi Arabia may reflect the extensive population
flows between the Kingdom, other part of the Middle East,
and North Africa where OXA-48 is widespread and the Indian
subcontinent where NDM are common (Nordmann et al.,
2011).Table 5 Comparison between phenotypic assays (MicroScan and M
Strain No. Species MHT MicroScan
ERT MIC
1 K. pneumoniae ve S 60.25
3 K. pneumoniae +ve R 2
5 K. pneumoniae +ve R 2
6 K. pneumoniae +ve R 2
7 K. pneumoniae ve S 0.5
8 K. pneumoniae ve R >1
9 K. pneumoniae +ve R >1
15 K. pneumoniae +ve R >1
30 E. coli +ve S 60.25
41 E. coli +ve R 2
47 K. pneumoniae +ve R >1
48 K. pneumoniae +ve R 4
56 K. pneumoniae +ve R >1Thus awareness of carpbapenemase producing Enterobac-
teriaceae in Gulf cooperation council countries has important
implications for controlling the spread of carpbapenemase
producing Enterobacteriaceae in the Middle East and in hospi-
tals accommodating patients transferred from the region
(Zowawi et al., 2014). Thus after we evaluated phenotypic
and molecular tests, we recommend using molecular tests such
Gene Expert R assay for optimal carbapenemnase detection
and it is important to know the type of carbapenemase gene
present, reducing material, manpower and cost (Doyle et al.,
2012), besides recommendation for an initial screening for
Enterobacteriaceae by using ertapenem in addition to merope-
nem and imipenem.
Acknowledgements
This research project was supported by a grant from the
‘‘Research Center of the Female Scientific and Medical Col-
leges”, Deanship of Scientific Research, King Saud University.HT) and Xpert Carba-R molecular assay.
Xpert Carba-R
IMI MIC MER MIC
S 61 S 61 OXA-48
S 61 R 61 OXA-48
S 61 S 61 OXA-48
S 61 S 61 OXA-48
S 61 S 61 OXA-48
R >8 R >8 NDM
I 2 S 61 OXA-48
S 61 S <1 OXA-48
S 61 S 61 -ve
S 2 S 61 OXA-48
S 61 S 61 OXA-48
S 61 S 61 OXA-48
S <1 S <1 OXA-48
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